RxDoctor Payments Data

Janet Tsang, MD

Clinical Cardiac Electrophysiology · Baltimore, MDNPI 1306038187

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (60.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Medtronic at 45.3% of the total. Reporting peaked in 2019 at $15,171 and has fallen 99.5% since, to $79 in 2025.

$20,530in general payments, 2019–2025

Across 96 payments — averaging $213.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Boston Scientific$9K
  • Abbott$2K
  • Medical Device Business Services, Inc.$145
  • Lantheus Medical Imaging, Inc.$122
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$94
  • plus $57 from 3 others

What the payments were for

  • Grants$12,31760%
  • Travel & lodging$3,86319%
  • Food & beverage$3,71118%
  • Education$6393%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,530 in reported general payments places this provider in the 60th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

See all clinical cardiac electrophysiology providers in Maryland

Medicare billing

Part B allowed, 2024
$219,126
Medicare patients
815
Services billed
1,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$145,548
EntrestoSacubitril/Valsartan57$92,907
JardianceEmpagliflozin34$50,461
XareltoRivaroxaban20$30,273
Metoprolol Succinate127$2,259
Atorvastatin Calcium98$1,646
Rosuvastatin Calcium33$1,490
Carvedilol112$1,113
Ezetimibe20$1,053
Amiodarone Hcl35$786
Amlodipine Besylate81$729
Nifedipine ErNifedipine24$597
Flecainide Acetate12$513
Hydralazine Hcl21$472
Lisinopril34$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$13$92,90757 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 63 clinical cardiac electrophysiology providers in Maryland.

Other clinical cardiac electrophysiology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →